The association of adenosine A1 receptor gene variants with the multidrug-resistant partial seizure epilepsy
1.Department of Neurology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015; 2.Department of Neurology, Chenzhou NO.1 People Hospital, Chenzhou,423000; 3.The Eye Hospital of Wenzhou Medical University, Wenzhou, 325027; 4.Department of Transplantation, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015
XU Huiqin1,OU Fuyong2,NAREN Mandula1, et al. The association of adenosine A1 receptor gene variants with the multidrug-resistant partial seizure epilepsy[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2014, 44(2): 100-104.
Abstract：Objective: To explore the association of the single-nucleotide polymorphisms (SNP) of adenosine A1 receptor (A1AR) gene with partial pharmacoresistance seizure in south of Zhejiang province Han population. Methods: One hundred and twenty cases of partial seizure patients were obtained for this study, multidrug-resistant group and full controlled with no seizures group (followed: named the none pharmacoresistance group) each 60 cases, and 60 healthy patients as normal control group. A polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used for the detection of rs903361, rs10920573, rs3766553 SNP, via the retrospective case-control study and multiple logistic regression analysis methods to explore its correlation of drug resistance epilepsy. Rusults: Both the frequencies of the allelic of all SNPs among the three group and genotypes of three SNPs between the normal control and none pharmacoresistance group had no statistical difference. The frequency of rs903361 CT genotype in pharmacoresistance epilepsy patients was obviously lower than in the none pharmacoresistance group, P=0.017. The frequency of rs10920573 CT genotypes in pharmacoresistance epilepsy patients was obviously higher than in the none pharmacoresistance group, P=0.010. According to the multiple logistic regression analysis, the CC and TT genotypes in rs903361 were both the independent risk factor for pharmcoresistance in epileptic patients and associated with a 2.73 and 2.609 times added risk for pharmacoresistance than CT genotype, P=0.043 and 0.047 respectively. In rs10920573, CT genotype was also an independent risk factor for pharmcoresistance in epileptic patients,and associated with a 2.572 times increased risk for pharmacoresistance than TT genotype, P=0.037. There was no difference among all rs3766553 genotypes.Conclusion: The CC and TT genotypes of rs903361 and the CT of rs10920573 are both the independent risk factors associated with mulltidrug-resistant partial seizure epilepsy.
[1] Nadkarni S, LaJoie J, Devinssky O. Current treatments ofepilepsy[J]. Neurology, 2005, 64(12 Suppl 3): 2-11.
[2] Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy[J]. Epilepsia, 2001, 42 (12): 1501-1506.
[3] Ribeiro JA, Sebastiao AM, De Mendonca A. Adenosine re-ceptors in the nervous system: pathophysiological implicat-ions[J]. Prog Neurobiol, 2003, 68(6): 377-392.
[4] Wagner AK, Miller MA, Scanlon J, et al. Adenosine A1 receptor gene variants associated with post-traumatic seizures after severe TBI[J]. Epilepsy Research, 2010, 90(3): 259-272.
[6] Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system[J]. Annu Rev Neurosci,2001, 24: 31-55.
[7] Boison D. Adenosine-based cell therapy approaches for pharmacoresistant epilepsies[J]. Neurodegener Disorder,2007, 4(1): 28-33.
[8] Hernandez SD, Mccord JM. Association of a new intronic polymorphism of the SOD2 gene (G1677T) with cancer[J].Cell Biochem Funct, 2009, 27: 223-227.
[9] Rosen N, Chalifa-Caspi V, Shmueli O, et al. GeneLoc: exonbased integration of human genome maps[J]. Bioin-formatics, 2006, 19(S1): i222-i224.
[10] Fredholm BB, Ijzerman AP, Jacobson KA, et al. Interna-tional Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors[J]. Pharmacol Rev,2001, 53(4): 527-552.
[11] Avsar E, Empson RM. Adenosine acting via A1 receptors,controls the transition to status epilepticus-like behaviour in an in vitro model of epilepsy[J]. Neuropharmacology,2004, 47(3): 427-437.
[12] Ohta Y, Nariai T, Kurumaji A,et al.Increased binding of inhibitory neuronal receptors in the hippocampus in kainate-treated rats with spontaneous limbic seizures[J]. J CliniNeurosci, 2010, 17(5): 612-616.
[13] Rebola N, Porciuncula LO, Lopes LV, et al. Long-term ef-fect of convulsive behavior on the density of adenosine A1 and A2A receptors in the rat cerebral cortex[J]. Epilepsia,2005, 46 Suppl 5: 159-165.
